...
首页> 外文期刊>mSphere >Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
【24h】

Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors

机译:结核分枝杆菌MMPL3的多种突变增加了对MMPL3抑制剂的抗性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The Mycobacterium tuberculosis protein MmpL3 performs an essential role in cell wall synthesis, since it effects the transport of trehalose monomycolates across the inner membrane. Numerous structurally diverse pharmacophores have been identified as inhibitors of MmpL3 largely based on the identification of resistant isolates with mutations in MmpL3. For some compounds, it is possible there are different primary or secondary targets. Here, we have investigated resistance to the spiral amine class of compounds. Isolation and sequencing of resistant mutants demonstrated that all had mutations in MmpL3. We hypothesized that if additional targets of this pharmacophore existed, then successive rounds to generate resistant isolates might reveal mutations in other loci. Since compounds were still active against resistant isolates, albeit with reduced potency, we isolated resistant mutants in this background at higher concentrations. After a second round of isolation with the spiral amine, we found additional mutations in MmpL3. To increase our chance of finding alternative targets, we ran a third round of isolation using a different molecule scaffold (AU1235, an adamantyl urea). Surprisingly, we obtained further mutations in MmpL3. Multiple mutations in MmpL3 increased the level and spectrum of resistance to different pharmacophores but did not incur a fitness cost in vitro . These results support the hypothesis that MmpL3 is the primary mechanism of resistance and likely target for these pharmacophores. IMPORTANCE Mycobacterium tuberculosis is a major global human pathogen, and new drugs and new drug targets are urgently required. Cell wall biosynthesis is a major target of current tuberculosis drugs and of new agents under development. Several new classes of molecules appear to have the same target, MmpL3, which is involved in the export and synthesis of the mycobacterial cell wall. However, there is still debate over whether MmpL3 is the primary or only target for these classes. We wanted to confirm the mechanism of resistance for one series. We identified mutations in MmpL3 which led to resistance to the spiral amine series. High-level resistance to these compounds and two other series was conferred by multiple mutations in the same protein (MmpL3). These mutations did not reduce growth rate in culture. These results support the hypothesis that MmpL3 is the primary mechanism of resistance and likely target for these pharmacophores.
机译:结核分枝杆菌蛋白MMPL3在细胞壁合成中表现了重要作用,因为它影响了海藻糖醇在内膜的运输。已经基于MMP1中的突变鉴定,许多结构不同的药理鉴定为MMPL3的抑制剂。对于一些化合物,可以存在不同的初级或次要靶标。在这里,我们研究了对螺旋胺类化合物的抗性。抗性突变体的分离和测序证明所有mMPL3中的突变。我们假设如果存在该药镜的额外目标,则连续的圆形以产生抗性分离物可能会揭示其他基因座中的突变。由于化合物仍然有效抗抗性分离物,尽管具有降低的效力,但在较高浓度下,我们在该背景中分离出抗性突变体。在用螺旋胺的第二轮分离后,我们发现MMPL3中的额外突变。为了增加我们发现替代目标的机会,我们使用不同的分子支架(Au1235,亚氨基脲脲)耗尽了第三轮隔离。令人惊讶的是,我们在MMPL3中获得了进一步的突变。 MMPL3中的多个突变增加了不同药物抗性的水平和光谱,但不产生体外的健身成本。这些结果支持假设MMPL3是抗性的主要机制,并且可能对这些药物的靶标。重要性结核分枝杆菌是一种主要的全球性质病原体,迫切需要新的药物和新药靶标。细胞壁生物合成是目前结核病药物和开发新试剂的主要目标。几种新的分子似乎具有相同的目标MMPL3,其参与了分枝杆菌细胞壁的出口和合成。但是,仍然争论MMPL3是这些类的主要还是仅目标。我们希望确认一个系列的阻力机制。我们确定了MMPL3中的突变,导致螺旋胺系列的抗性。通过同一蛋白质(MMPL3)中的多个突变赋予了对这些化合物和另外两种化合物的高水平抗性。这些突变没有降低培养的生长速率。这些结果支持假设MMPL3是抗性的主要机制,并且可能对这些药物的靶标。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号